As chair of the biotechnology group and a member of the firm’s food and agriculture steering committee, Dr. Meghan Poon counsels clients on patent preparation and prosecution, portfolio strategy, and IP due diligence in the areas of life science and agriculture. Meghan is passionate about working with cutting edge technologies at the frontier or science that impacts human health and global food security. She has significant experience in diverse technologies including antibodies, cell and gene therapies, diagnostics, and gene edited plants. Meghan manages a cross-technology team to service clients developing technology at the interface of life science and AI.
Meghan represents clients ranging from large international pharmaceutical companies to midsized companies, startups, and universities. She has filed numerous Patent Term Extension applications to secure additional term for her clients’ patents which cover FDA approved products. In addition, Meghan has extensive experience addressing complex obviousness-double patenting and subject matter eligibility issues impacting her clients’ patent portfolios. Meghan also represents clients in both investor side and target side due diligence in deals from seed funding to initial public offerings.
Meghan is a thought leader on intellectual property issues facing pharmaceutical, biotechnology, and agriculture companies and is sought after to speak at events and publish on these issues. Meghan has written numerous articles on the topics of patents vs. trade secrets, subject matter edibility, written description and enablement in life sciences. Meghan is editor of the MoFo Life Sciences Blog, where she directs content.
Prior to law school, Meghan earned her PhD in biological chemistry based at the University of California, Los Angeles. Meghan’s Ph.D. work focused on analysis of protein-protein and protein-DNA interactions of site-specific recombinases. Meghan is the author of several scientific publications and has presented her research at international conferences.
Meghan received her J.D. from the University of Southern California Law School and spent a year as a visiting student at Santa Clara University, where she focused on intellectual property.
Gates Ag One
Advise the world’s largest family foundation on strategy and patent portfolio development and assist with various investments and licensing matters, including assisting the Foundation’s subsidiary, Gates Ag One with developing intellectual property for programs aimed at improving photosynthesis and nitrogen use efficiency in plants.
Genentech
Counsel Genentech, the world’s most successful biotechnology company and part of the Roche family of companies, on developing the company’s strategy for its multibillion-dollar portfolios, including blockbuster cancer drugs Kadcyla, Perjeta, Gazyva, Tecentriq, and Polivy.
Inari
Represent Inari, a plant breeding technology company working to build a more sustainable global food system through its SEEDesign platform, for patent prosecution of AI and gene editing technologies.
Juno Therapeutics
Counsel Juno Therapeutics, a biopharmaceutical company focused on cancer cell therapy, in the IP due diligence that was the basis for a significant portion of the valuation for its $9 billion acquisition by Celgene (now Bristol-Myers Squibb). We continue to lead strategy on the Juno portfolio following the acquisition.
Ohalo Genetics
Advise Ohalo Genetics on patent strategy for technology related to novel breeding systems in plants. Ohalo’s Boosted Breeding technology aims to accelerate variety development, produced higher yielding corps, and allows production of true seed in vegetatively propagated crops.
Meiogenix
Direct patent prosecution strategy for the gene editing technologies developed by Meiogenix, that are used to unlock the natural genetic diversity of wild crops.
Attralus
Represent Attralus, a clinical stage biotech company on intellectual property strategy and patent prosecution for its patent portfolio that covers diagnostics for amyloid-related diseases and large molecules used to treat amyloid-related diseases.
Sonoma Therapeutics
Patent counsel for Sonoma Therapeutics, an emerging clinical-stage company that focuses on cell therapies to treat inflammatory diseases.